Menu
Exonate
Exonate develops and licenses Vascular Endothelial Growth Factors (VEGF) control agents that may be used as therapeutics in areas such as pain control, macular degeneration and cancer.
Drug discovery – wet AMD and cancer
School of Medicine
Profile
Exonate’s research in this area has identified therapeutic candidates for wet Age Related Macular Degeneration that can be administered as a simple eye drop, thereby over-coming the unpleasant need for monthly injections in the eye.
Competing injectable anti-VEGFdirected therapy currently constitutes the gold-standard treatment for wet Age Related Macular Degeneration (wAMD) and other neovascular diseases of the eye.
News and press releases
@ExonateUK on Twitter
At Exonate we are celebrating pride month by highlighting LGBT+ Scientists who have and continue to make the world a better place with their innovations and discoveries.
#PrideMonth2021 #Pride2021 #prideinstem
Diversity and Inclusion in #ClinicalTrials is a top priority for our teams. Janssen's Cassandra Smith discusses how this is essential to achieving health equity. For more info, check out: https://bit.ly/3fkHQFK
#CTAW2021
Today we’re marking #IDAHOBIT2021 and standing strong with our #LGBT colleagues in support of equality. At GSK, we’re committed to an inclusive workplace where all employees feel a sense of belonging and can be their authentic selves. 🌈
Learn more: https://gsk.to/2SRqMQd
You might not see the early signs of vision loss, but your eye doctor can. Regular check-ups, especially if you fall into a high-risk category, are the best way to prevent vision loss. Learn more: https://bit.ly/33PiLh1
#HealthyVisionMonth #Retina
Today is the first day of #ClinicalTrials
Awareness Week! This week, we celebrate patients, their caregivers and study investigators. Advances in clinical research wouldn't be possible without their dedication. #CTAW2021
Janssen's Francoise Lethiec speaks to how we are bringing #ClinicalTrials directly to participants, making it easier to integrate trials into their everyday lives through an initiative called Trials2You. #CTAW2021
Today at @AusBiotech’s #AusMedtech2021 conference, Tim Schmid, Johnson & Johnson Asia Pacific Company Group Chairman of Medical Devices, shared thoughts on driving innovation, keeping connections and delivering real world advancements in medical technology.
This year’s #HealthyVisionMonth theme is equity in eye health. Follow @NatEyeInstitute as they highlight eye health professionals from different backgrounds and share simple steps everyone can take to protect their vision now. Learn more at: https://bit.ly/3eEGA13
#Retina
